Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 16/20 | 0.69 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.59 |
| ▸ | AURKA | O14965 | 2/20 | 0.59 |
| ▸ | LCK | P06239 | 2/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.59 |
| ▸ | FLT3 | P36888 | 2/20 | 0.59 |
| ▸ | SYK | P43405 | 2/20 | 0.59 |
| ▸ | CDC7 | O00311 | 1/20 | 0.59 |
| ▸ | PLK4 | O00444 | 1/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.59 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.59 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.59 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.59 |
| ▸ | PAK4 | O96013 | 1/20 | 0.59 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769817 | 1.00 | KDR (0.69) | KDRAURKBIRAK4AURKALCK | |
| SCHEMBL1000873 | 0.83 | KDR (0.70) | KDRAURKBIRAK4AURKALCK | |
| SCHEMBL1000875 | 0.83 | KDR (0.70) | KDRAURKBIRAK4AURKALCK | |
| SCHEMBL3772758 | 0.82 | AURKB (1.00) | KDRAURKBIRAK4AURKALCK | |
| SCHEMBL3779854 | 0.82 | AURKB (1.00) | KDRAURKBIRAK4AURKALCK | |
| SCHEMBL1002524 | 0.81 | KDR (0.68) | KDRAURKBIRAK4AURKALCK | |
| SCHEMBL1002521 | 0.81 | KDR (0.68) | KDRAURKBIRAK4AURKALCK | |
| SCHEMBL3553074 | 0.81 | KDR (0.68) | KDRAURKBIRAK4AURKALCK | |
| SCHEMBL1001585 | 0.81 | KDR (0.67) | KDRAURKBIRAK4AURKALCK | |
| SCHEMBL1001583 | 0.81 | KDR (0.67) | KDRAURKBIRAK4AURKALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426408-B2 | Pyrimidine inhibitors of kinases | ABBVIE INC. (US) | 2013-04-23 | — | — | US | claimed |
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | US | claimed |
| US-8426408-B2 | Pyrimidine inhibitors of kinases | ABBVIE INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | AURKA, AURKC, AURKB | KDR 38/4885AURKB 3/4885IRAK4 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.